A Study of Aleglitazar in Combination With Oral Contraceptive Healthy Volunteers
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This randomized, double-blind, placebo-controlled, cross-over study will assess the effect of aleglitazar on the pharmacokinetics and pharmacodynamics on Microgynon® in healthy volunteers. Volunteers will receive multiple oral doses of aleglitazar in one period; in the other period volunteers will receive placebo.
Single-Center, Randomized, Double-Blind, Placebo Controlled, Crossover Study to Assess the Effect of Aleglitazar on the Pharmacokinetics and Pharmacodynamics of Ethinyl Estradiol and Levonorgestrel as Components of the Oral Contraceptive Microgynon®
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 45 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Healthy female volunteer, 18 to 45 years of age
Body mass index (BMI) between 18.0 and 29.9 kg/m2
Body weight at least 55.0 kg
Non-pregnant, not lactating and not planning pregnancy from screening to 3 months after the last dose of study treatment
Non-smoker for at least 3 months
Currently active gynecological disorder
History of amenorrhea within the previous 3 years
Known or suspected history of estrogen-dependent neoplasia or sex hormone-dependent malignant tumors
Use of steroid hormone-containing intrauterine device (IUD) or progesterone-release IUD contraceptive within 3 months to screening.
History of clinically significant disease that could jeopardize the volunteer safety in the study